1341 related articles for article (PubMed ID: 18171206)
1. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
[TBL] [Abstract][Full Text] [Related]
5. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.
Armstrong GL; Billah K; Rein DB; Hicks KA; Wirth KE; Bell BP
Pediatrics; 2007 Jan; 119(1):e22-9. PubMed ID: 17200247
[TBL] [Abstract][Full Text] [Related]
6. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
Trotter CL; Edmunds WJ
Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.
De Wals P; Nguyen VH; Erickson LJ; Guay M; Drapeau J; St-Laurent J
Vaccine; 2004 Mar; 22(9-10):1233-40. PubMed ID: 15003652
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
10. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
[TBL] [Abstract][Full Text] [Related]
12. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].
da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I
Sante; 2003; 13(4):215-23. PubMed ID: 15047438
[TBL] [Abstract][Full Text] [Related]
13. Pertussis in adolescents and adults: should we vaccinate?
Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
[TBL] [Abstract][Full Text] [Related]
14. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of varicella vaccination in Spain: results from a dynamic model.
Lenne X; Diez Domingo J; Gil A; Ridao M; Lluch JA; Dervaux B
Vaccine; 2006 Nov; 24(47-48):6980-9. PubMed ID: 16860909
[TBL] [Abstract][Full Text] [Related]
16. Regional variation in the cost effectiveness of childhood hepatitis A immunization.
Jacobs RJ; Greenberg DP; Koff RS; Saab S; Meyerhoff AS
Pediatr Infect Dis J; 2003 Oct; 22(10):904-14. PubMed ID: 14551492
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.
Ray GT; Whitney CG; Fireman BH; Ciuryla V; Black SB
Pediatr Infect Dis J; 2006 Jun; 25(6):494-501. PubMed ID: 16732146
[TBL] [Abstract][Full Text] [Related]
18. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
Trotter CL; Gay NJ; Edmunds WJ
Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
[TBL] [Abstract][Full Text] [Related]
19. Could a federal program to promote influenza vaccination among elders be cost-effective?
Patel MS; Davis MM
Prev Med; 2006 Mar; 42(3):240-6. PubMed ID: 16480761
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
